Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
211.3 USD | +2.96% | -10.29% | -8.67% |
Financials (USD)
Sales 2024 * | 75.33M | Sales 2025 * | 361M | Capitalization | 4.37B |
---|---|---|---|---|---|
Net income 2024 * | -578M | Net income 2025 * | -389M | EV / Sales 2024 * | 48.9 x |
Net cash position 2024 * | 694M | Net cash position 2025 * | 292M | EV / Sales 2025 * | 11.3 x |
P/E ratio 2024 * |
-7.24
x | P/E ratio 2025 * |
-11.3
x | Employees | 376 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.94% |
Latest transcript on Madrigal Pharmaceuticals, Inc.
1 day | -0.81% | ||
1 week | -10.70% | ||
Current month | +0.60% | ||
1 month | -13.25% | ||
3 months | -5.12% | ||
6 months | +47.83% | ||
Current year | -11.29% |
Managers | Title | Age | Since |
---|---|---|---|
Edward Chiang
FOU | Founder | - | 11-08-31 |
William Sibold
CEO | Chief Executive Officer | - | 23-09-07 |
Rebecca Taub
FOU | Founder | 71 | 16-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 78 | 11-08-31 | |
Julian Baker
CHM | Chairman | 57 | 23-06-14 |
Ken Bate
BRD | Director/Board Member | 73 | 16-07-21 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.35% | 0 M€ | 0.00% | - | |
0.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 211.3 | +2.96% | 269 883 |
24-05-10 | 205.2 | -0.81% | 234,068 |
24-05-09 | 206.9 | -0.54% | 359,475 |
24-05-08 | 208 | -4.55% | 690,496 |
24-05-07 | 218 | -7.48% | 780,739 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.29% | 4.37B | |
+3.91% | 109B | |
+10.87% | 105B | |
+0.15% | 22.25B | |
-13.14% | 22.09B | |
-7.68% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- MDGL Stock